EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 20 / Numéro 4 (Avril 2004) Med Sci (Paris), 20 4 (2004) 453-457 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 4, Avril 2004
Page(s) 453 - 457
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004204453
Publié en ligne 15 avril 2004
  1. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12 : 421–9. [Google Scholar]
  2. Jeannel D, Hubert A, de Vathaire F, et al. Diet, living conditions and nasopharyngeal carcinoma in Tunisia - a case-control study. Int J Cancer 1990; 46 : 421–5. [Google Scholar]
  3. Laouamri S, Hamdi-Cherif M, Sekfali N, et al. Facteurs de risque alimentaires du carcinome du nasopharynx dans la région de Sétif (Algérie). Rev Epidemiol Sante Publique 2001; 49 : 145–56. [Google Scholar]
  4. Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002; 31 : 395–9. [Google Scholar]
  5. Mokni-Baizig N, Ayed K, Ayed FB, et al. Association between HLA-A/-B antigens and -DRB1 alleles and nasopharyngeal carcinoma in Tunisia. Oncology 2001; 61 : 55–8. [Google Scholar]
  6. Dardari R, Khyatti M, Jouhadi H, et al. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. Int J Cancer 2001; 92 : 294–7. [Google Scholar]
  7. Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein-Barr virus strains in asymptomatic carriers. J Virol 2003; 77 : 1840–7. [Google Scholar]
  8. Nicholls J, Hahn P, Kremmer E, et al. Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material. J Virol Methods 2004; 116 : 79–88. [Google Scholar]
  9. Edwards RH, Sitki-Green D, Moore DT, Raab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol 2004; 78 : 868–81. [Google Scholar]
  10. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003; 63 : 8293–301. [Google Scholar]
  11. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001; 98 : 6905–10. [Google Scholar]
  12. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt’s lymphoma. EMBO J 2002; 21 : 954–65. [Google Scholar]
  13. Tsimbouri P, Drotar ME, Coy JL, Wilson JB. Bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene 2002; 21 : 5182–7. [Google Scholar]
  14. Khabir A, Ghorbel A, Daoud J, et al. Similar BCL-X but different BCL-2 levels in the two age groups of North African nasopharyngeal carcinomas. Cancer Detect Prev 2003; 27 : 250–5. [Google Scholar]
  15. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, et al. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 2000; 60 : 5584–8. [Google Scholar]
  16. Gulley ML, Nicholls JM, Schneider BG, et al. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998; 152 : 865–9. [Google Scholar]
  17. Ablashi D, Bornkamm GW, Boshoff C, et al. Proceedings of the IARC Working Group on the evaluation of carcinogenic risks to humans. Epstein-Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. Lyon, France, 17-24 June 1997. IARC Monogr Eval Carcinog Risks Hum 1997; 70 : 1–492. [Google Scholar]
  18. Dardari R, Hinderer W, Lang D, et al. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients : complementary test of ZEBRA protein and early antigens p54 and p138. J Clin Microbiol 2001, 39 : 3164–70. [Google Scholar]
  19. Chan KCA, Lo YMD. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12 : 489–96. [Google Scholar]
  20. Liu HX, Ding YQ, Li X, Yao KT. Investigation of Epstein-Barr virus in Chinese colorectal tumors. World J Gastroenterol 2003; 9 : 2464–8. [Google Scholar]
  21. Shimakage M, Kawahara K, Sasagawa T, et al. Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression. Hum Pathol 2003; 34 : 1170–7. [Google Scholar]
  22. Zur Hausen A, Brink AA, Craanen ME, et al. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas : expression of the transforming BARF1 gene. Cancer Res 2000; 60 : 2745–8. [Google Scholar]
  23. Huang J, Chen H, Hutt-Fletcher L, et al. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 2003; 77 : 13267–74. [Google Scholar]
  24. Feng WH, Israel B, Raab-Traub N, et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002; 62 : 1920–6. [Google Scholar]
  25. Li JH, Shi W, Chia M, et al. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther 2003; 8 : 964–73. [Google Scholar]
  26. Ferlay J, Bray F, Pisani P, Parkin DM. IARC cancerBase n° 5. Lyon : IARC Press, 2001. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.